VYNE Therapeutics Inc. (VYNE)
Market: NASD |
Currency: USD
Address: 685 Route 202/206 N
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Show more
📈 VYNE Therapeutics Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$6.50
-
Upside/Downside from Analyst Target:
591.20%
-
Broker Call:
6
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
25-50%
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.055556 |
- |
2023-02-13 |
- |
Stock split |
|
Total Amount for 2023: $0.055556 |
| 2021 |
- |
$0.250000 |
- |
2021-02-16 |
- |
Stock split |
|
Total Amount for 2021: $0.250000 |
📅 Earnings & EPS History for VYNE Therapeutics Inc.
| Date | Reported EPS |
|---|
| 2026-03-04 (estimated upcoming) | - |
| 2025-11-05 (estimated upcoming) | - |
| 2025-11-04 (estimated upcoming) | - |
| 2025-08-12 (estimated upcoming) | - |
| 2025-08-11 (estimated upcoming) | - |
| 2025-05-08 | -0.2 |
| 2025-05-06 | - |
| 2025-03-06 | -0.28 |
| 2025-02-25 | - |
| 2024-11-07 | -0.29 |
| 2024-08-14 | -0.22 |
| 2024-08-13 | -0.22 |
| 2024-05-09 | -0.15 |
| 2024-05-08 | -0.15 |
| 2024-02-29 | -0.2 |
| 2024-02-28 | -0.2 |
| 2023-11-13 | -2.01 |
| 2023-11-12 | -2.01 |
| 2023-08-14 | -3.09 |
| 2023-08-13 | -3.09 |
| 2023-05-11 | -1.74 |
| 2023-05-10 | -1.74 |
| 2023-03-09 | -3.33 |
| 2023-03-08 | -3.33 |
| 2022-11-10 | -2.88 |
| 2022-11-09 | -2.88 |
| 2022-08-12 | -2.34 |
| 2022-08-11 | -2.34 |
| 2022-05-12 | -2.52 |
| 2022-05-11 | -2.52 |
| 2022-03-17 | -3.6 |
| 2022-03-16 | -3.6 |
| 2021-11-10 | -6.48 |
| 2021-11-09 | -6.48 |
| 2021-08-12 | -6.3 |
| 2021-08-11 | -6.3 |
| 2021-05-06 | -6.66 |
| 2021-05-05 | -6.66 |
| 2021-03-04 | -9.9 |
| 2021-03-03 | -9.9 |
| 2020-11-05 | -10.8 |
| 2020-11-04 | -10.8 |
| 2020-08-06 | -14.4 |
| 2020-08-05 | -14.4 |
| 2020-05-11 | -68.4 |
| 2020-05-10 | -68.4 |
| 2020-03-03 | -64.08 |
| 2020-03-02 | -64.08 |
| 2019-10-30 | -50.4 |
| 2019-07-31 | -49.68 |
| 2019-05-01 | -58.32 |
| 2019-02-26 | -54.72 |
| 2018-11-06 | -40.32 |
| 2018-07-31 | -25.92 |
| 2018-05-08 | -51.84 |
| 2018-03-27 | -129.6 |
| 2018-01-25 | - |
📰 Related News & Research
No related articles found for "vyne therapeutics".
